Bin-CE: A comprehensive web application to decide upon the best set of outcomes to be combined in a binary composite endpoint by Marsal Mora, Josep Ramon et al.
RESEARCH ARTICLE
Bin-CE: A comprehensive web application to
decide upon the best set of outcomes to be
combined in a binary composite endpoint
Josep Ramon MarsalID
1,2,3,4, Ignacio Ferreira-González1,2*, Aida Ribera1,2,
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Abstract
The estimation of the Sample Size Requirement (SSR) when using a binary composite end-
point (i.e. two or more outcomes combined in a unique primary endpoint) is not trivial.
Besides information about the rate of events for each outcome, information about the
strength of association between the outcomes is crucial, since it can determine an increase
or decrease of the SSR. Specifically, the greater the strength of association between out-
comes the higher the SSR. We present Bin-CE, a free tool to assist clinicians for computing
the SSR for binary composite endpoints. In a first step, the user enters a set of candidate
outcomes, the assumed rate of events for each outcome and the assumed effect of therapy
on each outcome. Since the strength of the association between outcomes is usually
unknown, a semi-parametric approach linking the a priori clinical knowledge of the potential
degree of association between outcomes with the exact values of these parameters was
programmed with Bin-CE. Bin-CE works with a recursive algorithm to choose the best com-
bination of outcomes that minimizes the SSR. In addition, Bin-CE computes the sample size
using different algorithms and shows different figures plotting the magnitude of the sample
size reduction, and the effect of different combinations of outcomes on the rate of the pri-
mary endpoint. Finally, Bin-CE is programmed to perform sensitivity analyses. This manu-
script presents the mathematic bases and introduces the reader to the use of Bin-CE using
a real example.
Introduction
The use of a binary Composite Endpoint (CE) in clinical trials, defined as the combination of
two or more dichotomous variables in a unique endpoint, is common[1,2]. Particularly when
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a binary CE is used as the primary endpoint, a patient experiences the primary endpoint if any
of the specific components occurs [2]. The two main reasons for using CE instead of a single
primary outcome [3–6] are a) the utility of the CE to assess the ‘net benefit’ of a therapy and b)
the utility of the CE to reduce the Sample Size Requirement (SSR) by increasing the total num-
ber of observed events [7]. For instance, an intervention designed to decrease the rate of myo-
cardial infarction in primary prevention by reducing LDL cholesterol, may reduce total
cardiovascular mortality but also the rate of cerebrovascular events. Thus, the use of the CE
“Major Adverse Cardiovascular Event (MACE)” including the outcomes myocardial infarc-
tion, cardiovascular mortality, and stroke could better capture the net benefit of the interven-
tion. However, this use of CE can also complicate the interpretation of the results of the trial
[3,5,6,8–10].
The potential of a binary CE to reduce the SSR is closely related to the magnitude of associa-
tion between components[11]. In this sense, not all CE have the same potential in the SSR
reduction. For example, imagine a hypothetic and bizarre binary CE defined as “Acute Coro-
nary Syndrome (ACS)” or “Troponin Elevation above the normal level”. A patient experiences
the CE if any of both events occurs. However, both variables are so strongly associated that
they practically mean the same. Therefore, it is unlikely that the combination of them in a
binary CE increases the number of events and thus its capacity to reduce SSR. On the other
hand, consider a binary CE defined as “ACS” or “stroke”. In this case, although it is anticipated
that a certain number of patients may suffer both events these variables are “moderately corre-
lated”, and the number of patients experiencing at least one of the components would be
expected to be higher than the number of patients experiencing ACS or stroke if they had been
employed as a single primary outcome [12]. In a previous work [12] we assessed the impact of
the strength of the association between two components of a binary CE on the SSR. Specifi-
cally, the stronger the association between both components the lower the potential reduction
of SSR. In addition, the potential impact of the strength of the association between compo-
nents to modulate the SSR is influenced by both the prevalence of outcomes and the effect of
the therapy on each outcome.
In the present work, our previous findings with a binary CE with only two dichotomous
components are generalized to a binary CE with k dichotomous components. Specifically, we
present an Internet accessible computational tool that incorporates a simple method to assess
the SSR and helps a trialist to decide upon combining a set of candidate outcomes in a unique
CE. The algorithm has been programmed in a free tool that, starting from k possible candidate
outcomes, finds the best combination which minimizes the SSR, using or not all k compo-
nents. This tool named Bin-CE is available as a beta version in https://uesca-apps.shinyapps.
io/bincep/. We also present a numeric example to illustrate the inputs and outputs of Bin-CE.
Material and methods
Notation and assumptions
We define a Relevant Endpoint (RE) as the outcome that is assumed to drive the main effect of
the therapy. An Additional Endpoint (AE) is another outcome that the researcher considers to
combine with the RE in a binary CE to reduce the SSR. A CE could be built up from one RE
and k additional endpoints. For simplicity, the statistical test applied by default is the asymp-
totic approximation to the Normal distribution of the difference in the proportion of events
between groups[7,13,14]. However, other approximations could be selected for those SSRs that
are assumed not be large (i.e. arcsine approximation and with/without correction). We shall
consider also for simplicity a RCT with only two treatment arms. The aim of the algorithm is
to compute the SSR of both the CE (SSRCE) and the RE (SSRRE). If the SSR of the CE is smaller
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than the SSR of the single RE then researcher would prefer the use of the CE [15] instead of the
RE alone (i.e. SSRCE < SSRRE).
Let Xijk be the binary response of the j-th patient (j = 1, . . ., ni) in the i-th group (i = 1,2) for
the k-th outcome (k = 1, . . ., K). The algorithm assumes the same number of patients in each
group (n1 = n2) and that at least two outcomes are considered to be combined (K>1). The Rel-
evant Endpoint is codified with k = 1 and the Additional Endpoint uses the remaining sub-
scripts (k>1). E(Xijk) = πik and V(Xijk) = πik(1−πik). Imagine a specific two-component binary
CE that combines two outcomes, the RE (Xijk = 1) and the k’-th AE (Xijk = k0), we denote this as
X1k0ij and note that is equal to 1 whenever Xijk = 1 or Xijk = k0 are equal to 1 and 0 otherwise. X
1k0
ij
is distributed as a Bernoulli random variable with mathematical expectation:
EðX1k0ij Þ ¼ ProbðX
1k0
ij ¼ 1Þ ¼ ProbððXij1 ¼ 1Þ [ ðXijk0 ¼ 1ÞÞ ¼ ProbðXij1 ¼ 1Þ þ ProbðXijk0
¼ 1Þ   ProbððXij1 ¼ 1Þ \ ðXijk0 ¼ 1ÞÞ ¼ pi1 þ pik0   pi;1k0 ð1Þ
, where πi,1k0 corresponds to the probability of both outcomes (i.e. RE and the k’-th AE) hap-
pening together. Note that with these six parameters (πi = 1,1,πi = 1,k0,πi = 1,1k0,πi = 2,1,πi = 2,k0,
πi = 2,1k0) the SSR of the RE and the CE can be determined[7,16] and thus it can become appar-
ent whether it is worth the combination of the RE with the AE in a CE. Usually πi1,πik, are
known, but πi,1k0 is sometimes unknown[17].
It should be noted that the parameter πi,1k0 equals the joint probability between the RE and
the k’-th AE and it measures the strength of association between them. We assume that the
association between outcomes is the same in both study groups. The probability of both out-
comes occurring together is the same in the two arms. Henceforth πi,1k0 it will be referred as
π1k0.
Quantification of the strength of association between components of a CE
Although there are many different coefficients to quantify the strength of association between
components of a binary CE (see Supplementary Material for some examples, S1 File), we have
chosen the join probability for simplicity because the other coefficients are more or less com-
plex functions derived from both the join probability and the marginal probabilities.
On the early sixties, the work by Fréchet[18] on the combination of probabilities of events
and by Bahadur[19] on the joint probability distribution of binary random variables, charac-
terized the probability of two outcomes happening together (πkk0). It was shown that the distri-
bution is bounded between a lower and an upper limit and that not all values between 0 and 1
are possible. These bounds, known as Fréchet bounds, depend on the marginal prevalence of
each outcome as follows:
0 � Lowðpi1; pik0 Þ ¼ maxf0; pi1 þ pik0   1g � p1k0 � minfpi1; pikg ¼ Upðpi1; pik0Þ � 1 ð2Þ
When π1k0 = πi1πik0 both outcomes are considered as not being associated or as independent
events. For instance, imagine a CE including the outcomes “ACS or stroke”, these are consid-
ered independent if the probability of a patient experiencing an ‘ACS’ is the same regardless
the patient had a ‘stroke’ previously and vice versa.
Bin-CE algorithm
Bin-CE is a free available web application that can be accessed using a web browser (https://
uesca-apps.shinyapps.io/bincep/). Bin-CE has been programmed using the Shiny library on R
Studio. The R statistical language[20] has been used to develop Bin-CE App on R Studio. Bin-
CE can be directly run by connecting with the Shiny server https://www.shinyapps.io/)
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without need to install neither R Studio or Shiny package. Nevertheless, users with program-
ming notions of R language can download the source code at Supplementary Material, S2. File
All necessary functions to implement Bin-CE can be found in S2 File. Functions, figures and
general structures have been programed by ourselves. Using the Supplementary Material 2 you
can replicate the examples given in this paper and Supplementary Material 3 contributes with
a deeper mathematical approach.
Bin-CE has been programmed to select, from a set of candidate binary outcomes (K�10),
the combination that minimizes the SSR. The four-screens that conform Bin-CE are automati-
cally refreshed when any input data changes (Fig 1). The first two screens are used to upload
all necessary data. The third screen is used only to check all input data and to present the initial
results. When Bin-CE detects any inconsistency in the input data such as a joint probability
outside the Fréchet bounds, it is automatically corrected. For example, consider that the user
introduces a rate of 6% for the RE and 10% for the AE and a joint probability value of 8%. The
joint probability value is not possible since in this case, it is defined only in the range 0% to
6%. Accordingly, Bin-CE automatically corrects this mistake by assigning the product of mar-
ginal probabilities for the joint probability (i.e. 0.6%), assuming the non-association scenario.
Finally, the last screen displays the best combination of outcomes (if any exists) in a CE as well
as the corresponding SSR. This screen also shows the intermediate steps of algorithm
iterations.
Analysis workflow
Step 1.1: Input data (Screen 1: Rate of events and effect of the therapy). Bin-CE allows
up to nine outcomes that may be combined with the RE. Bin-CE permits allows uploading the
label, the rate of events (πi = 1,k) in the control group, and the assumed effect of the therapy for
each outcome. In addition, the user can choose the Type I and Type II errors. The effect can be
assessed using different parameters (i.e. difference of proportions, rate-ratio, odds ratio). For the
following discussion we will assume that the effect is estimated by the Relative Risk (RR)
(πi = 1,k/πi = 2,k) because it is better suited as a measure of intervention effect in clinical trials
[21]. In any case, RR and Odds Ratio (OR) are numerically easily interchangeable [22] using
the expression 3. Additionally, the user can determine the component that drives the main
effect of the therapy or, in other words, the RE. If no outcome is indicated, Bin-CE automati-











Fig 1. Bin-CE workflow.
https://doi.org/10.1371/journal.pone.0209000.g001
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Step 1.2: Input data (Screen 2: Joint probability). Bin-CE uses the joint probability as a
parameter to quantify the degree of association between outcomes (i.e. second-order associa-
tion). If values of joint probabilities between outcomes were known by the user they can be
assigned manually. However, as usually their exact values are unknown, Bin-CE permits to
enter semi-parametric approximations based on the Fréchet bounds (Fig 3). In this option,
nine different scenarios are considered depending on the assumed magnitude and direction of
the association between outcomes. One scenario considers that outcomes are non-associated.
In this case Bin-CE internally assigns the association for independent events (i.e. πkk0 = πikπik0).
Additionally, there are two specific scenarios, one for the maximum and another for the mini-
mum possible association (i.e. minimum and maximum Fréchet bound). For instance, the
association between the outcomes “CV death” and “Death from any cause” is the maximum
possible association (i.e. all CV death can be considered as “death from any cause”) whereas
the association between “ischemic stroke” and “hemorrhagic stroke” is the minimum possible
association (i.e. they can be considered as mutually exclusive). There are also three scenarios
indicating negative association: strong, moderate, and low negative association, and three sce-
narios indicating positive association (i.e. strong, moderate, and low positive association).
Bin-CE imputes the joint probability using: a) the marginal prevalence of each outcome
(πik,πik0); b) the range between minimum and maximum of the Fréchet bound (High(πik,πik0)
−Low(πik,πik0)); and finally, c) the non-association scenario (πkk0 = πikπik0). In (4) it is shown
the mathematical expression applied when the user considers that outcomes are not associated,
whereas in (5) and (6) the expressions for the negative and positive association are displayed.
pkk0 ¼ pikpik0 ð4Þ
pkk0 ¼ pikpik0  




Fig 2. Data showed on screen 1: Rate of events and effect of the therapy. On the first screen (Input Data), the user
fixes the number of outcomes, the hypothesis contrast and the type I/II errors assumed. Then the user assigns the
following parameters a) the label of each outcome, b) the rate of events in the control group, c) the effect of the therapy
measured as a risk ratio and d) if any of the outcomes is considered as the RE.
https://doi.org/10.1371/journal.pone.0209000.g002
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pkk0 ¼ pikpik0 þ




The parameter Θ takes value 1 for low, 2 for moderate, and 3 for strong positive/negative
associations. The user can combine exact joint probabilities for some pairs of outcomes and
semi-parametric approximations for other pairs.
On the third screen (Fig 4), Bin-CE shows the input data. Graphically, Bin-CE shows on
this screen a plot with the potential increase or decrease in the SSR when the RE is combined
Fig 3. Data showed on screen 2: Joint probability (second-order association). On the second screen (Association)
the known joint probabilities for the simultaneous occurrence of each pair of outcomes should be declared and their
values uploaded in the appropriate cell. The semi-parametric approximations according to the Fréchet Bounds are
employed for the unknown associations.
https://doi.org/10.1371/journal.pone.0209000.g003
Fig 4. Data showed on Screen 3: Checking upload data and firsts results. On the third screen (Data) the user can
check the data uploaded (i.e. labels, the RE, the rate of events in the control groups, the effect of the therapy and a
triangular-matrix with all the pairs of joint probabilities). On this screen the SSR for the RE or for the outcome with a
minimum SSR is shown. Finally, Bin-CE depicts a plot with the range of SSR when combining the RE with each of the
other AE assuming the lower and the higher association of the Fréchet Bounds.
https://doi.org/10.1371/journal.pone.0209000.g004
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with each one of the other additional outcomes, but without taking into account the degree of
association considered. The plot depicts the SSR for both the minimum and maximum associ-
ation for each pair of outcomes with the RE. This plot can be useful to determine the impact of
the strength of association on the SSR. Also, on this screen, Bin-CE shows the SSR for the RE.
Step 2: An iterative algorithm. In the first iteration of the algorithm, Bin-CE computes
the SSR of the RE (SSRRE) and the (k-1) possible SSRs of the hypothetical two-components
CEs when combining the RE and the other AE (SSRk = 2 . . . K). From all possible additional out-
comes Bin-CE selects the one that combined with the RE leads to the largest decrease in the
SSRRE. Then, this combination of the RE and the AE with the lowest SSR is considered as the
new RE and the algorithm starts again seeking among the k-2 remaining outcomes. Bin-CE
additionally estimates the rate of the CE (1) and the effect of the CE on the treatment group
(the methodology to compute these parameters has been discussed previously [7,14,16]).
The joint probability between the new RE and all other AE candidates has now to be recalcu-
lated. Fig 5, shows three hypothetical outcomes (A, B and C). In this example the outcomes A and
B combined in a CE (CEAB) can decrease the SSR of the initial RE (i.e. A outcome). Then the joint
probability between the CEAB and the outcome C (i.e. a second order association) is red-colored.
The joint probability between AC and BC is known or have been estimated using the semi-
parametric approach, but the joint probability between the three outcomes (i.e. the third-order
association: πABC) is unknown. To solve this issue, it is assumed a non-associated scenario as a
good approximation of the third-order association, πABC = πAC�πAB.
If a new CE of three components with lower SSR that the CE of two components exists, this
new three-components-CE is in turn considered as the new provisional RE, and the algorithm
starts the process again until either all k-1 AE are included in the CE or there is no additional
gain in the SSR.
Fig 5. Second and third-order associations between three hypothetical outcomes (A, B and C). The association
between a new hypothetical CE obtained by combination of outcomes A and B and the outcome C (red-colored
probability) is the result of combining the joint probability between the pairs of outcomes A and C and the outcomes B
and C. The value of this probability is (1): Prob((XAC = 1)\(XBC = 1)) = πAC+πBC−πABC�πAC+πBC−πAC�πBC. Then
Bin-CE estimates the unknown joint probability among the 3 outcomes πABC with the product of both probabilities
(i.e. πAC�πBC). Although this is only an approximation, the potential error should be small since the real proportion of
patients with the 3 outcomes has to be within the Fréchet Bounds (max{0;πAC+πBC−1}�πABC�min{πAB,πBC}).
https://doi.org/10.1371/journal.pone.0209000.g005
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Step 3: Results (Screen 4: Table and plots output). Bin-CE shows a table that includes
the best combination of outcomes, the rate of events, the effect of the therapy on the CE, the
SSR estimated and the percentage of SSR reduction achieved in each step (Fig 6). It also pres-
ents several figures showing sequential changes of both SSR, event rates and intervention effect
(RR) at each iteration (Fig 7).
Numerical example
The STEMI-RADIAL study [23] is a randomized, multicenter, parallel group trial. Patients
that were admitted with an acute STEMI, within 12 h of symptom onset, and referred for an
invasive approach were randomized to a radial or a femoral approach. The underlying hypoth-
esis was that radial approach is safer than femoral approach.
The primary endpoint was the cumulative incidence of major bleeding and vascular access
site complications requiring intervention at 30 days. The components of the CE were: gastro-
intestinal bleeding, hemoglobin drop� 4g/dl without overt bleeding, hemoglobin� 3g/dl
with overt bleeding, hematoma > 15 cm, transfusion (non-coronary artery bypass graft), and
vascular access complication. Secondary outcomes at 30 days include Major Adverse Cardio-
vascular Event, defined as combinations of death, myocardial infarction, stroke and coronary
artery bypass graft. Since STEMI-RADIAL study included both ischemic and bleeding out-
comes we illustrate the performance of Bin-CE using separately both set of outcomes
(Table 1). Figs 2, 3, 4, 6 and 7 refers to the bleeding set of outcomes.
Using data from STEMI-RADIAL trial, we illustrate the selection of the most efficient com-
bination among the five bleeding outcomes (i.e. 31 possible combinations) and the 4 ischemic
outcomes (i.e. 15 possible combinations) in two CEs, one for the bleeding outcomes and the
ischemic outcomes, employing Bin-CE.
Results
The association between each pair of components is not available in the STEMI-RADIAL pub-
lication. Although it is highly recommended, the report of the association between individual
components is generally inadequate [2,24,25]. Since the present paper has an educational pur-
pose we assume absence of association among individual outcomes of the STEMI-RADIAL
clinical trial. Bin-CE imputes the product of both probabilities when non-associations scenario
is clicked (i.e. see Eq (4)).
Bin-CE workflow
In a first step (Fig 2), the user introduces the assumed rate of events in the radial group, the
assumed effect of the therapy, and the degree of association between each pair of outcomes
(Fig 3). If the exact degree of association between two pairs of outcomes is unknown, the semi-
Fig 6. Data showed on screen 4: Results (table). Each line presents the CE selected in each step, specifically: the label
of the combined components, the incidence rate and the Relative Risk, the SSR (number of subjects required in each
treatment group) and the proportion of SSR compared to that used for the isolated RE.
https://doi.org/10.1371/journal.pone.0209000.g006
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parametric approach is employed. Then, Bin-CE returns the joint probabilities between each
pair of component outcomes (Fig 4). In the bleeding example, associations between compo-
nents are unknown. In this example, for simplicity it is assumed that outcomes are not
associated.
Fig 7. Data showed on screen 4. Plots of the main results. A Sample Size Requirement in each iteration. Y-axis is
ranged from zero and it represents the SSR computed within each iteration. X-axis shows each one of the Bin-CE
iterations. In the example, first iteration corresponds to the RE “Hematoma> 15 cm.”, with SSR of 166. The second
iteration corresponds to the CE “Hematoma> 15 cm” and “Hb drop�3 g/dl with overt bleeding”, with a SSR of 121.
Finally Bin-CE proposes to combine 4 outcomes to the last CE, in this case the SSR is of 102. B Effect of the therapy in
each Bin-CE iteration. In the example, the effect of the therapy was a RR of 0.09 in the first iteration and it increased
(decreased the efficacy) until 0.16 at the last iteration of Bin-CE. C Rate of events in each iteration. This plot presents,
for each Bin-CE iteration, the rate of events for both the control group and the treatment group. In the example, the
rate of event for the control and treatment group in the first iteration were 6% and 0.54% respectively, which increased
to 9.48% and 1.33% in the second iteration. Finally, a small increase in rates was achieved through the third and fourth
iteration, in agreement with the small reduction in SSR displayed in A.
https://doi.org/10.1371/journal.pone.0209000.g007
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Bin-CE plots the potential SSR using the different combinations between the RE and each
AE (see bottom of the Fig 4). Note that the exact value of the association is not implemented in
this plot. Rather the plot shows the potential SSR variation for each combination of outcomes
considering the whole range of joint probabilities according to the Fréchet bounds. In the
example, the SSR of the CE “Hematoma > 15 cm or Hb drop�3gd/dl with overt bleeding”
could be as low as 117 or as high as 191 in case of minimum and maximum degree of associa-
tion respectively. Any component can be declared as RE; in the example ‘Hematoma > 15 cm’
does this role. By defect Bin-CE considers the component which needs a minimum SSR as the
RE.
Figs 6 and 7A show the CE with the lowest SSR. In this case the combination of
‘Hematoma > 15 cm’, ‘hemoglobin� 3g/dl with overt bleeding, ‘gastrointestinal bleeding and
‘vascular access complication’ would have provided the lowest SSR (n = 102 per group). More-
over, using this combination, a 38.55% (i.e. 61.45% of the initial SSR) reduction of the SSR
employing the primary outcome “Hematoma > 15 cm.” would have been achieved (166 vs.
102). It is also shown that the combination of “Hematoma > 15 cm” and “hemoglobin� 3g/dl
with overt bleeding” contributes the most to SSR, achieving a reduction of 27.11%. Therefore,
although the addition of the outcome “gastrointestinal bleeding” or “vascular access complica-
tion” further reduces the SSR, the magnitude of this reduction is so small (i.e. from 121 to 108
and from 108 to 102) that its inclusion in the CE could be debatable. The other outcomes are
not selected by Bin-CE because when their inclusion does not reduce the SSR. Fig 7B and 7C
show the variation on the rate of events and the effect of therapy, respectively, at each iteration.
Sensitivity analysis. Since the actual strength of association between some outcomes is
unknown and cannot be easily inferred, an additional analysis has been performed considering
combinations of the all nine possible semi-parametric values of the strength of association
between the five outcomes of the trial (Tables 2 and 3).
Table 2 presents the sensitivity analysis for bleeding outcomes and Table 3 the sensitivity
analysis for the ischemic outcomes. For the bleeding outcomes, the strength of association is
more determinant than in the ischemic example in terms of SSR. So the strength of association
Table 1. Primary and secondary outcomes in STEMI-RADIAL clinical trial.
Radial (n = 348) Femoral (n = 359) Effectb
n % n % RR OR Diff
Ischemic Outcomes
Death 8 2.30% 11 3.06% 1.33 1.34 0.77%
Infarction 4 1.15% 3 0.84% 0.73 0.72 -0.31%
Stroke 1 0.29% 1 0.28% 0.97 0.97 -0.01%
CABG/Revascularization 32 9.20% 28 7.80% 0.85 0.84 -1.40%
Bleeding Outcomes
GI Bleeding 5 1.44% 1 0.28% 0.19 0.19 -1.16%
Hb drop� 4 g/dl without overt bleeding 2 0.57% 1 0.28% 0.48 0.48 -0.30%
Hb drop� 3gd/dl with overt bleeding 13 3.74% 3 0.84% 0.22 0.22 -2.90%
Hematoma > 15 cm. 21 6.03% 2 0.56% 0.09 0.09 -5.48%
Transfusiona 3 0.86% 0 0.00% 0.00 0.00 -0.86%
Vascular Access Complication 4 1.15% 1 0.28% 0.24 0.24 -0.87%
a: Transfusion was excluded for the analysis because none case in Femoral group was observed. In this particular case, the effect is unlikely.
b: The effect is presented as the ratio between the incidences (risk ratio), using Odds Ratio see expression (3) and by the difference of incidences. Bin-CE uses the Risk
Ratio
GI: Gastrointestinal, Hb: Hemoglobin, Diff: Difference of incidences, RR: Risk Ratio, OR: Odds Ratio.
https://doi.org/10.1371/journal.pone.0209000.t001
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determines the set of events to combine. Thus, for the bleeding events, as the magnitude of
positive association decreases the number of combined outcomes rapidly increases, being the
lowest magnitude of association (i.e. disjoint outcomes) the most favorable scenario for the CE
(SSR = 97). In summary, for the bleeding events the strength of associations between outcomes
has a strong influence on both the number of bleeding outcomes to be combined in the CE
and SSR reductions (from 166 to 97, representing the 58% of the initial SSR).
On other hand, the strength of association hardly determines the number of components
combined in the ischemic CE. In this case the outcomes ‘coronary artery bypass graft’ and
‘myocardial infarction’ are consistently gathered in a CE regardless the degree of association,
except for the scenario with the highest degree of association where Bin-CE proposes only use
a single outcome. As Table 3 shows the influence of the degree of association on the SSR is
modest for the ischemic events (i.e. a maximum reduction of 26% on ischemic example vs. a
42% reduction in the bleeding example).
The sensitivity analysis not only has to be considered for the degree of association between
events. For example, in STEMI-RADIAL Trial the effect of some events could not be estimated
accurately (i.e. Hb. drop� 4 g/dl without overt bleeding). A small number of patients had the
event, and in this situation the variability of the effect can be high. Thus, simulating different
scenarios with different effects as a sensitivity analyses is advisable because it will provide
robustness.
Table 2. Sensitivity analysis. Bin-CE results when the strength of associations varies from the lowest to the highest possible values. Bleeding Outcomes.
Strength of
Association





Lowest Hematoma> 15-Hb�3 with-GI Bleeding-Access Compl-Hb�4 5 12.80% 0.18 97 58.43%
Strong Negative Hematoma> 15-Hb�3 with-GI Bleeding 3 11.01% 0.15 105 63.25%
Moderate Negative Hematoma> 15-Hb�3 with-GI Bleeding 3 10.92% 0.15 106 63.86%
Low Negative Hematoma> 15-Hb�3 with-GI Bleeding-Access Compl 4 11.84% 0.16 101 60.84%
No Association Hematoma> 15-Hb�3 with-GI Bleeding-Access Compl 4 11.72% 0.16 102 61.45%
Low Positive Hematoma> 15-Hb�3 with-GI Bleeding-Access Compl 4 9.40% 0.14 122 73.49%
Moderate Positive Hematoma> 15-Hb�3 with-GI Bleeding 2 7.74% 0.14 149 89.76%
Strong Positive Hematoma> 15-GI Bleeding 2 6.33% 0.10 160 96.39%
Highest Hematoma> 15 1 6.00% 0.09 166 100%
Hb: Hemoglobin, GI: Gastrointestinal.
https://doi.org/10.1371/journal.pone.0209000.t002
Table 3. Sensitivity analysis. Bin-CE results when the strength of associations varies from the lowest to the highest possible values. Ischemic Outcomes.





Lowest CABG-Infarction 2 10.35% 0.84 4724 73.62%
Strong Negative CABG-Infarction 2 10.32% 0.84 4771 74.35%
Moderate Negative CABG-Infarction 2 10.30% 0.84 4819 75.10%
Low Negative CABG-Infarction 2 10.27% 0.84 4867 75.85%
No Association CABG-Infarction 2 10.24% 0.84 4917 76.62%
Low Positive CABG-Infarction 2 9.98% 0.84 5230 81.50%
Moderate Positive CABG-Infarction 2 9.72% 0.84 5580 86.96%
Strong Positive CABG-Infarction 2 9.46% 0.85 5973 93.08%
Highest CABG 1 9.20% 0.85 6417 100%
CABG: coronary artery bypass graft.
https://doi.org/10.1371/journal.pone.0209000.t003
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Discussion
As long as the use of CEs in clinical trials increases steadily, the need for simple and robust
methods for a comprehensive use of this tool arises. We present a computational method to
guide decisions concerning the optimal choice of the number of dichotomous outcomes to be
combined in a binary CE in order to minimize the SSR. It also permits to explore a variety of
plausible scenarios by varying the assumed strength of association between the outcomes,
which can be useful to evaluate the potential usefulness of using CE in each clinical situation.
Eventually this could avoid the futile recruitment of patients in clinical trials, which will benefit
the researches, patients, and the scientific community. However, the time-to-event analysis
can be approximated though working with the probability of event by a certain follow-up time
as a binary outcome, so the sample should not be very different with both approximations.
Although there are many publications addressing the statistical methods to analyze the data
from clinical trials using CEs, the problem of the sample size computation and its relationship
with the strength of association between components of a binary CE has not been addressed in
depth [7,12,15,17,26,27]. Sozu et al.[7] reported the mathematical approach to estimate the
SSR of a CE and our group[16] explored how the strength of association between the 2 compo-
nents of a CE can affect this SSR. In the field of survival analysis, Gómez et al. have reported
several findings concerning the SSR when using CE in the time-to-event setting [15,28–31]. In
this manuscript we present Bin-CE, a free intuitive Shiny App available at https://uesca-apps.
shinyapps.io/bincep/ with the objective of computing the SSR of a binary CE with more than
two potentially candidate endpoints. It has to be noted that the iterative algorithm developed
to compute the SSR is not an exact method. Thus, some degree of error is assumed because of
the categorical approximation of the second-order associations and the imputation of the
third-order association using the mathematical expectation. However, the exact solution
would imply the estimation of 2k−1 coefficients (for instance, for PARADIGHM-HF study
[32], with 5 outcomes it should be necessary to estimate 31 parameters), which is not practical
in most situations. However, our sensitive analyses assuming different strengths of association
between outcomes indicate that the potential SSR error is not relevant from the clinical point
of view (Table 2).
Bin-CE has been designed to help the applied trialist so we have tried the software to be
intuitive and easily manageable. In a first step, the user determines the number of component
candidates and the prespecified type I and II error rates. Secondly, the user assigns the labels
and inputs the prevalence and the assumed effect of the therapy. Finally, the users have to
include the degree of the association between components, which is obviously a hard issue
because in most cases this parameter is unknown. In this sense, the App allows to introduce
the exact association (i.e. the joint probability) if it is known, which in most cases will not be
the case, or to use a semi-parametric approximation based on the Fréchet bounds otherwise.
The semi-parametric approximation is, in our view, a pragmatic solution, since for clinicians it
is usually easy to intuitively know whether components are correlated or not and, in the case
of correlation, if it is positive or negative and the rough strength of the association.
As a limitation, the reliability of Bin-CE lies on the validity of the assumption that the math-
ematical expectation (product of probabilities) is a good approximation of the third-order
associations between outcomes. However, as it is shown in the sensitivity analysis, the potential
error considering different levels of associations is unlikely to be clinically relevant.
Bin-CE uses a greedy step-wise forward iterative algorithm to find the optimal combina-
tion. So, Bin-CE solves locally the problem (i.e. to combine the RE with the AE whom establish
the lowest SSR) in each step. However, although we assume that the final combination of out-
comes in a CE selected by Bin-CE is the most efficient, it cannot be demonstrated. Such
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demonstration would require simulating all possible combinations from all available out-
comes, which would overcharge the programme.
In this article, we have focused on the issue of improving efficiency in clinical trials through
the minimization of SSR, provided there are a set of potential candidate outcomes available.
However, the importance of other critical considerations in the decision to use a CE (clinical
relevance of single components, homogeneity of intervention effects, interpretability of results,
etc.) should not be underemphasized[3–5].
There are several types of CE depending on the type of outcomes to be combined. Time-to-
event CE are by far the most used CE in clinical trials, although there are many other possibili-
ties (i.e. multivariate normal outcomes or multinomial variables as Likert scales). In this sense,
binary outcomes are used when the outcomes occur in a short-fixed follow-up period or when
the outcome has to be dichotomized. Although binary CE are much less used in clinical trials,
they are very useful to implement new knowledge on this topic because their mathematic
properties are well-stablished. Other authors [7,28,33–35] have used binary CE to illustrate
their proposes. In any case, a clear limitation of the present paper is that our findings cannot
be extrapolated directly to time-to event analyses.
In spite of that, we believe that our work is conceptually valid also in survival analysis in the
sense that an influence of the outcomes association and of the prevalence on the sample size
requirement is also required [15,29,36].
Bin-CE selects the best set of outcomes comparing the SSR for the RE versus the combina-
tion of RE with one of the AE remaining. The SSR is computed considering the simplest
hypothesis testing case of equality of probabilities. This approximation is simpler enough
when the number of outcomes to be combined is either large (i.e. multiplicity testing problem)
or other type of hypotheses testing is desired (e.g. at least one of the components is significant).
Some authors have studied in depth[33,37–39], the problem of multiple testing and the hetero-
geneity of possible contrasts applied giving some recommendations to handle it. We share the
source code (Supplementary Material 2) in order to adapt Bin-CE code to other particular
specifications.
An essential difference between Bin-CE and other tools to compute SSR is that Bin-CE cal-
culates the SSR for the most efficient CE and not for other prespecified CEs. Thus, the clinical
trialists have to be aware that bin-CE does not take into account the clinical relevance of the
outcomes combinates, which must always be assessed by the researcher. In this paper, we
describe a new tool that could be useful to reduce the SSR when one is considering a CE as a
primary endpoint. However, not only the SSR but other issues must also be taken into consid-
eration when using a CE in order to correctly interpret the final CE. We and other authors
have address these issues previously [3,5,6,25,39–44].
So, although Bin-CE does not solve completely the SSR in CE issue, it can be considerate a
first step. In this sense, we encourage other researchers to improve the utility of this tool.
To summarize, in this manuscript a free tool to estimate the SSR in a two-arms randomized
clinical trial using a binary CE with more than two-components is presented. When a set of
possible candidate outcomes is to be combined in a CE and the decision to combine them or
not depends on the SSR Bin-CE can be a good tool to consider. Accessible at: https://uesca-
apps.shinyapps.io/bincep/.
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Supervision: Ignacio Ferreira-González, Aida Ribera, David Garcı́a-Dorado.
Validation: Josep Ramon Marsal, Aida Ribera, Jose Ignacio Pijoan.
Visualization: Josep Ramon Marsal.
Writing – original draft: Josep Ramon Marsal, Ignacio Ferreira-González, Gerard Oristrell,
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